3
Announcements
Trials
Browse
Landscape
Status
Approved for marketing
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
5
Expanded_access
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Hairy Cell
1
Leukemia
1
Interventions
fludarabine phosphate
2
tisagenlecleucel
1
revumenib
1
ponatinib
1
midostaurin
1
immunotoxin HA22
1
glucarpidase
1
fludarabine
1
Whole-Body Irradiation
1
Tacrolimus
1
Mycophenolic Acid
1
HA 22
1
Cytarabine
1
Cyclophosphamide
1
Cord Blood Stem Cell Transplantation
1
Carboxypeptidases
1
Busulfan
1
Bone Marrow Transplantation
1
AP 1903 reagent
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Expanded_access
×
Leukemia
×
immunotoxin HA22
×
Clear all
NCT03501615
2020-06-29
MOXE
AstraZeneca
Approved for marketing